Lumino Medicine

Lumino Medicine is a clinical-stage biotechnology company focused on developing precision medicines for neuropsychiatric and neurological disorders. Headquartered in Cambridge, Massachusetts, the company was founded and is backed by Apple Tree Partners (ATP). Lumino's lead program, LM-001, is a first-in-class, oral, selective small molecule agonist of GPR139, a G protein-coupled receptor primarily expressed in the habenula region of the brain. LM-001 is currently in Phase 2 clinical development for the treatment of Major Depressive Disorder (MDD). The company's approach combines deep expertise in GPCR pharmacology with neurocircuitry insights to address the limitations of current psychiatric treatments. By targeting specific brain regions involved in mood regulation, Lumino aims to provide rapid and sustained relief for patients with high unmet needs.